Table 1.
Baseline characteristics
| N=25 | |
| Gender, n (%) | |
| Female | 11 (44) |
| Male | 14 (56) |
| Age, median years (range) | 66 (33–86) |
| Body mass index (kg/m2), median (range) | 19.9 (16.1–27.0) |
| Race, n (%) | |
| Asian | 25 (100) |
| Histology, n (%) | |
| Adenocarcinoma | 20 (80) |
| EGFRm (+) | 7 (28) |
| EGFRm (-) | 9 (36) |
| EGFRm NA | 4 (16) |
| Squamous cell carcinoma | 4 (16) |
| Large cell carcinoma | 1 (4) |
| Prior treatment history* | |
| Surgery + Chemo | 7 (28) |
| Surgery + Rad | 2 (8) |
| Surgery + Chemo + Rad | 6 (24) |
| Chemo | 5 (20) |
| Chemo + Rad | 5 (20) |
| Checkpoint blockade | 3 (12) |
*Tyrosine kinase inhibitors are included in Chemo (+).